Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1697 • ACR Convergence 2023
Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
Ioannis Parodis¹, Julius Lindblom¹, Guillermo Barturen², Rafaela Ortega Castro³, Ricard Cervera⁴, Jacques-Olivier Pers⁵, Fernanda Genre Romero⁶, Falk Hiepe⁷, Maria Gerosa⁸, Laszlo Kovacs⁹, Ellen De Langhe¹⁰, Silvia Piantoni¹¹, Georg Stummvoll¹², Carlos Vasconcelos¹³, Barbara Vigone¹⁴, Torsten Witte¹⁵, Marta Alarcon-Riquelme¹⁶ and Lorenzo Beretta¹⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France, ⁶IDIVAL, Santander, Spain, ⁷Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁸University of Milan, Milano, Italy, ⁹University of Szeged, Szeged, Hungary, ¹⁰Katholieke Universiteit Leuven and Universitair Ziekenhuis Leuven, Leuven, Belgium, ¹¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹²Medical University Vienna, Baden, Austria, ¹³Centro Hospitalar do Porto, Porto, Portugal, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁵Dept of Immunology and Rheumatology, Hannover, Germany, ¹⁶Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Treating to remission or lupus low disease activity state (LLDAS) are conceptual frameworks for the management of SLE, but the biological milieus underlying these…
Abstract Number: 2035 • ACR Convergence 2023
Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous
Emmanuel Campos-Tinajero¹, Griselda Serna-Peña², Jorge A. Esquivel-Valerio¹, Rodrigo J. Castillo-de la Garza³, Gisela García Arellano⁴, Pablo Gamez-Siller¹, Estefania Aguilar-Rivera⁵, Patricia L. Gonzalez-Garcia¹ and Dionicio A. Galarza-Delgado⁶, ¹Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory, multisystemic, chronic disease more prevalent in women and can significantly impact health-related quality of life (HRQoL).1 Sociodemographic…
Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
Abstract Number: 2285 • ACR Convergence 2023
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update
J. Patricia Dhar¹, Hannah Forsythe², Louis Saravolatz¹ and Susanna Szpunar³, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Detroit, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St. John Hospital, Detroit, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
Abstract Number: 2302 • ACR Convergence 2023
Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus
Rachel Koelmeyer¹, Kate gregory¹, Rangi Kandane-Rathnayake², Fiona Goldblatt³, Sean O’Neill⁴, Maureen Rischmueller⁵, Mandana Nikpour⁶, Geraldine Hassett⁷, Pravin Hissaria⁸, Darakanathan Ranganathan⁹, Claire Barrett¹⁰, Ashleigh Hennessey⁹, Ted Tsai¹¹, Peter Gowdie¹², Eric Morand¹³ and Alberta Hoi¹⁴, ¹Monash University, Clayton, Australia, ²Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ³Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ⁴Department of Medicine, University of New South Wales, Kensington, Australia, ⁵The Queen Elizabeth Hospital and Basil Hetzel Institute; Adelaide Medical School, University of Adelaide, Adelaide, Australia, ⁶The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ⁷Liverpool Hospital, Liverpool, Australia, ⁸Royal Adelaide Hospital, Adelaide, Australia, ⁹Royal Brisbane and Women's Hospital, Herston, Australia, ¹⁰Redcliffe Hospital, Redcliffe, Australia, ¹¹Canberra Hospital, Garran, Australia, ¹²Monash Health, Clayton, Australia, ¹³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ¹⁴Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia
Background/Purpose: Previous studies in childhood-onset systemic lupus erythematosus (cSLE) have suggested that cSLE patients have more severe disease, compared to those with adult-onset disease (aSLE).…
Abstract Number: 2318 • ACR Convergence 2023
The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study
Vrati Mehra¹, Daniela Dominguez², Nicholas Gold², Andrea Knight², Deborah Levy², Fangming Liao², Eleanor Pullenayegum², Amer Shammas², etienne Sochett², Reza vali², Declan Webber³, Earl Silverman⁴ and Linda Hiraki², ¹The Hospital for Sick Children & University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴Silverman, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus patients < 18 years (cSLE) are at risk for reduced bone mineral density (BMD) due to disease activity and chronic…
Abstract Number: 2335 • ACR Convergence 2023
Defining a Basket Population for ANA+ Arthritis Trials
Jack Arnold¹, Md Yuzaiful Md Yusof¹, Lucy Carter², Zoe Wigston¹ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²University of Leeds, Hartlepool, United Kingdom
Background/Purpose: Musculoskeletal (MSK) manifestations are common in systemic lupus erythematosus (SLE) and other ANA-associated rheumatic musculoskeletal diseases (ANA-RMDs). Presently clinical trials recruit patients from individual…
Abstract Number: 2444 • ACR Convergence 2023
Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis
Eric Morand¹, Rachel Cheong², Peter Eggenhuizen², Janet Chang², Ashraf Broury², Boaz Ng², Khai Loh², Elean Tay², Chanjuan Shen³, Julie Monk², Yong Zhong⁴, Steven Lim², Jia Xi Chung², Rangi Kandane-Rathnayake⁵, Rachel Koelmeyer², Alberta Hoi⁶, Sarah Snelgrove², Yi Tian Ting² and Joshua Ooi², ¹Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²Monash University, Clayton, Australia, ³Central South University, Changsha, China, ⁴Xiangya Hospital, Central South University, Changsha, China, ⁵Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁶Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia
Background/Purpose: Regulatory T cells (Tregs) play an important role in maintaining immune system homeostasis. Antigen-specific Tregs potently and specifically suppress autoreactivity, suggesting their potential to…
Abstract Number: 2497 • ACR Convergence 2023
Factors Influencing Time to Diagnosis in U.S. Patients with Systemic Lupus Erythematosus
Joy Buie, Lupus Foundation of America, York, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease defined by its heterogeneity and cycles of flares and remissions. Owing to non-specific or incomplete…
Abstract Number: 2589 • ACR Convergence 2023
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus
Emily Zhang¹, Sarah Capponi², Rebecca Scobell³, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan⁴, Mindy Lo⁴, Olha Halyabar⁵, Melissa Hazen¹, Ezra Cohen⁶, Lauren Henderson¹, Siobhan Case⁷, Margaret Chang¹, Ankana Daga¹, Jonathan Hausmann⁸, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma⁴, Fatma Dedeoglu⁴, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁹, Mary Beth Son⁴ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Hospital of the University of Pennsylvania, New Hope, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Children's Hospital/Boston Medical Center, Newton, MA, ⁶Bmc, Needham, MA, ⁷Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁸Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic glucocorticoid (GC) morbidity is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The pediatric glucocorticoid toxicity index (pGTI) (Brogan et…
Abstract Number: 0033 • ACR Convergence 2023
A Novel Transcriptome-Based Machine Learning Pipeline Predicts Phenotypes of Lupus Patients
Emily Leventhal¹, Andrea Daamen¹, Amrie Grammer² and Peter Lipsky², ¹AMPEL BioSolutions, LLC, and The RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gene expression analysis coupled with machine learning (ML) holds the promise of identifying subsets of patients with heterogeneous diseases, such as systemic lupus erythematosus…
Abstract Number: 0141 • ACR Convergence 2023
In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis
Mishouri Paul, Prodip Paul, Birendra Amgai and Julio Ramos, Geisinger Community Medical Center, Scranton, PA
Background/Purpose: Systemic lupus erythematosus is a chronic inflammatory disorder that significantly burdens our health system. The study aimed to understand the difference in in-patient outcomes…
Abstract Number: 0192 • ACR Convergence 2023
Demographic and Clinical Factors That Contribute to Clinical Study Enrollment in Systemic Lupus Erythematosus
Sean Inzerillo¹, Noa Schwartz², Leila Khalili¹, Wai Yan April Fu², Wei Tang¹, Laura Geraldino-Pardilla¹, Yevgeniya Gartshteyn³, Nancyanne Schmidt¹, Peter Izmirly⁴ and Anca Askanase⁵, ¹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, New York, NY, ³Columbia University Medical Center, New York, NJ, ⁴New York University School of Medicine, New York, NY, ⁵Columbia University Medical Center, New York, NY
Background/Purpose: Participation in clinical trials is part of treatment for many patients with chronic diseases. However, patients with systemic lupus erythematosus (SLE), especially those of…
Abstract Number: 0546 • ACR Convergence 2023
Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis
Lu Liu, Karina de Leeuw, Suzanne Arends, Berber Doornbos-van der Meer, Harry van Goor and Johanna Westra, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Lupus nephritis (LN) is regarded as one of the most severe manifestations of systemic lupus erythematosus (SLE). This inflammation in the kidneys may lead…
Abstract Number: 0563 • ACR Convergence 2023
Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Mediator of the Association Between Particulate Matter Exposure and Disease Activity in Systemic Lupus Erythematosus
Ji-Hyoun Kang¹, Hyemin Jeong², Sung-Eun Choi², Dong-Jin Park², Han Joo Baek³, Hyo-Jin Choi⁴, Jae Hyun Jung⁵ and Shin-Seok Lee², ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ³Gil Medical Center, Gachon University College of Medicine, Inchon, South Korea, ⁴Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea, ⁵Korea University Ansan Hospital, Ansan-si, South Korea
Background/Purpose: Neutrophil gelatinase-associated lipocalin (NGAL) is an acute-phase glycoprotein increased by inflammatory stimuli, oxidative stress, and tissue injury. Although NGAL is associated with global and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].